AMRI Expands Sterile Production Capacity
AMRI, a global contract research, development and manufacturing organization, is expanding its sterile manufacturing capacity. The addition of an aseptic pre-filled syringe filling line at our manufacturing facility in Albuquerque, N.M., adds capacity to manufacture roughly 50 million syringes per year.
With the rise of biologics and the number of parenteral drugs under development and receiving approval poised to increase, pharmaceutical companies are looking for tailored drug delivery approaches for unit dose medication. Prefilled syringes offer many market and patient advantage opportunities such as API cost savings, reducing dosing errors and improved convenience and ease of use for patients saving them time and ultimately enhancing their quality of life.
“This investment supports our intent to ensure AMRI’s drug product solution has the capacity and technology to serve the increasing demand from our customers,” said David Stevens, SVP, Head of Drug Product. “Our comprehensive suite of sterile dosage form development and manufacturing capabilities are designed to meet the needs of biopharma throughout the entire life cycle of their sterile drug product. This expansion enhances the experience for our customers by delivering more of the benefits that AMRI’s best-in-class sterile dosage form capabilities and expertise has to optimize the path of projects from bench to market.”
About AMRI
AMRI, a global contract research and manufacturing organization, partners with the pharmaceutical and biotechnology industries to improve patient outcomes and quality of life. With locations in North America, Europe and Asia, AMRI’s team combines scientific expertise and market-leading technology to provide a complete suite of solutions in Discovery, Development, Analytical and Solid State Services, API Manufacturing and Drug Product. For more information about AMRI, visit www.amriglobal.com.
Total Page Views: 1214
